Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.46 |
| ▸ | XDH | P47989 | 4/20 | 0.45 |
| ▸ | GABRP | O00591 | 4/20 | 0.41 |
| ▸ | GABRD | O14764 | 4/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.41 |
| ▸ | GABRE | P78334 | 4/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.41 |
| ▸ | GABRG1 | Q8N1C3 | 4/20 | 0.41 |
| ▸ | GABRG3 | Q99928 | 4/20 | 0.41 |
| ▸ | GABRQ | Q9UN88 | 4/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6976559 | 0.83 | DAGLA (0.52) | DAGLAXDHGABRPGABRDGABRA1 | |
| SCHEMBL20663398 | 0.81 | KDM4E (0.53) | XDHGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL3640199 | 0.78 | DAGLA (0.56) | DAGLAXDHGABRPGABRDGABRA1 | |
| SCHEMBL4464221 | 0.75 | XDH (0.49) | XDHKMT2ATLR4KDM4ENLRP3 | |
| SCHEMBL29805838 | 0.75 | XDH (0.49) | XDHKMT2ATLR4KDM4ENLRP3 | |
| SCHEMBL2490866 | 0.73 | SMN1; SMN2 (0.49) | DAGLAXDHGABRPGABRDGABRA1 | |
| SCHEMBL5542616 | 0.73 | GABRP (0.42) | DAGLAXDHGABRPGABRDGABRA1 | |
| SCHEMBL17087993 | 0.72 | LMNA (0.43) | DAGLAXDHGABRPGABRDGABRA1 | |
| SCHEMBL6982900 | 0.72 | DAGLA (0.54) | DAGLAXDHGABRPGABRDGABRA1 | |
| SCHEMBL14110409 | 0.72 | DAGLA (0.67) | DAGLAXDHGABRPGABRDGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2627178-B1 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS | MERCK SHARP & DOHME (US) | 2018-05-02 | — | — | EP | disclosed |
| US-9290454-B2 | Substituted isoquinolines as CRTH2 receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150353498-A1 | SUBSTITUTED ISOQUINOLINES AS CRTH2 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | US | disclosed |
| EP-2922539-A1 | SUBSTITUTED ISOQUINOLINES AS CRTH2 RECEPTOR MODULATORS | Merck Sharp & Dohme Corp. (US) | 2015-09-30 | — | — | EP | disclosed |
| US-8927559-B2 | Quinazolinone-type compounds as CRTH2 antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927559-B2 | Quinazolinone-type compounds as CRTH2 antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927559-B2 | Quinazolinone-type compounds as CRTH2 antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-01-06 | — | — | US | disclosed |
| WO-2014055311-A1 | SUBSTITUTED ISOQUINOLINES AS CRTH2 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2014-04-10 | — | — | WO | disclosed |
| EP-2627178-A1 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2013-08-21 | — | — | EP | disclosed |
| US-20130210805-A1 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| US-20130210805-A1 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| US-20130210805-A1 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| WO-2012051036-A1 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-04-19 | — | — | WO | disclosed |
| WO-2012051036-A1 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210805-A1 | QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS | HRH2, NR3C2, HRH1 | DAGLA 4773/4885XDH 415/4885GABRP 2875/4885 |
| US-20150353498-A1 | SUBSTITUTED ISOQUINOLINES AS CRTH2 RECEPTOR MODULATORS | NR1H2, NR1H3, GPR52 | DAGLA 4286/4885XDH 1683/4885GABRP 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.